Nitric oxide (NO) and nanoparticles – potential small tools for the war against COVID-19 and other human coronavirus infections

Graphical abstract

Highlights

• •

  Nitric oxide has shown antiviral potential against respiratory viral infections.

• •

  Protocols of inhaled nitric oxide against COVID-19 are in current trial.

• •

  Current trials might indicate suitable parameters for nitric oxide treatment against COVID-19.

• •

  Nitric oxide allied to nanoparticles may improve the antiviral potential.

Abstract

The endogenous free radical nitric oxide (NO) plays a pivotal role in the immunological system. NO has already been reported as a potential candidate for use in the treatment of human coronavirus infections, including COVID-19. In fact, inhaled NO has been used in clinical settings for its antiviral respiratory action, and in the regulation of blood pressure to avoid clot formation. In this mini-review, we discuss recent progress concerning the antivirus activity of NO in clinical, pre-clinical and research settings, and its beneficial effects in the treatment of clinical complications in patients infected with coronaviruses and other respiratory viral diseases, including COVID-19. We also highlight promising therapeutic effects of NO donors allied to nanomaterials to combat COVID-19 and other human coronavirus infections. Nanomaterials can be designed to deliver sustained, localized NO release directly at the desired application site, enhancing the beneficial effects of NO and minimizing the side effects. Challenges and perspectives are presented to open new fields of research.